Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.

The pharmaceutical industry faces an innovation crisis with declining R&D productivity, rising costs, and regulatory challenges impacting drug development.

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) ('Ligand”) announced today the pricing of $400.0 million aggregate ...

The global peptide and anticoagulant drugs market is witnessing significant growth, driven by factors such as the rising prevalence of cardiovascular diseases, technological advancements, and the ...

The demand for renal transplant therapeutics is increasing due to several important factors. Chief among these is the global rise in kidney transplan ...

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

Archer Daniels Midland logged lower profit and revenue in the second quarter, hurt by what Chief Executive Juan Luciano called a challenging environment. Yum Brands logged higher profit and sales in ...

Archer Daniels Midland logged lower profit and revenue in the second quarter, hurt by what Chief Executive Juan Luciano called a challenging environment. Yum Brands logged higher profit and sales in ...

Pfizer Inc (NYSE: PFE) saw its shares rise by more than 4% after the company reported strong second-quarter results that ...

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...

Pfizer CEO Albert Bourla is expected to attend a $25 million fundraiser at US President Donald Trump’s golf club in ...